Gaudi Cathedral, Barcelona
It seems oddly surreal of my photo editor to remind me that on this day in the past we were in Barcelona (right) for some conference or other and this year’s EORTC-NCI-AACR Molecular Targets meeting (aka the Triple in industry parlance) was cancelled in Spain in favour of a virtual meeting, thanks to the ongoing pandemic.
There is no doubt that thinking big in cancer research is vitally important, but sometimes we have to consider the difference between building cathedrals for the long-term rather than building simple walls as short-term fixes.
Here we consider some examples in the context of oncology drug development and also open the monthly October BSB mailbag…
To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the EORTC-NCI-AACR Triple meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
“Find a bit of beauty in the world today. Share it. If you can’t find it, create it. Some days this may be hard to do. Persevere.” ~ Lisa B. Adams
In the first part of the review on novel targets in hematologic malignancies, we covered five key areas in detail relating to emerging new agents around BTK, BRD, BET, and E3 ligase modulators (CELMoDs).
Continuing our look at some additional novel targets and agents in early development in hematologic malignancies, in part two of this series we explore four additional areas that piqued our interest.
These mostly involve either small molecules or monoclonal antibodies.
In the next series, we shall look at emerging immunotherapy related targets, but for now there’s plenty of targeted therapies to focus on!
To learn more from our oncology coverage and get a heads up on insights emerging our latest analysis and commentary subscribers can log-in or you can click to gain access to BSB Premium Content.
A wet gloomy day in San Francisco was brightened up by some small biotech talks
San Francisco – The other day I mentioned that we could expect some cross pollination across several recent conferences and this latest post on Kura Oncology is one such example of that genre.
We’ve been following their story longitudinally for a while now and with a lot suddenly going on, 2020 could well turn out to be an crucial year for the company.
There is no doubt they have been pursuing a very focused precision medicine approach with tipifarnib and executing nicely on that strategy so far, but as more indications and additional pipeline agents move into the clinic do the same principles still apply?
To find out, we interviewed a couple of their senior executives and discussed both current progress as well as where they are headed…
To learn more from our oncology coverage and get a heads up on our latest commentary from the JPM and ASH annual meetings, subscribers can log-in or you can click to gain access to BSB Premium Content.
ASH19 Targeted Therapies Preview: This year’s ASH in Orlando is very much dominated by new developments on the immunotherapy front in terms of both T and NK cell therapies, with some passing interest in BTK inhibitors as well.
It’s not always sunny in Florida…
What about targeted therapies and the science behind those developments?
It was not that long ago that these were the main lifeblood of the meeting across many, if not most, hematologic malignancies. How times have changed!
That said, outside of the CARs (T and NK cells), as well as bispecific immunotherapies, and BTK inhibitors there are still some gems to be found amongst the rest of the ASH19 abstracts.
Here we highlight an additional 10 abstracts involving early pipeline areas that encompass some novel targets, new combination approaches, or emerging science.
Please note that the novel targets can take the form of classic targets or IO ones since they didn’t fit in the prior ASH Preview topics already reviewed under separate cover…
Curious to find out more about these intriguing selections and get a heads up on additional insights from our ASH19 commentary?Subscribers can log-in or you can click to gain access to BSB Premium Content.
Fall in Boston in time for TRIPLE19
Boston – It looks like being RAS week at the AACR-NCI-EORTC Triple meeting aka Targets19. Yesterday we explored the first-in-man data for the Mirati small molecule inhibitor, MRTX849, in KRASG12C mutant cancers that included lung and colon carcinomas.
In terms of aberrant activity in cancer, RAS comes in three different flavours, if you will – KRAS, NRAS, and HRAS.
After plenty of coverage of KRAS (and more yet to come!), it’s now time to turn our attention to a rather different oncogene driver and put HRAS to be in the spotlight. Here, we offer an updated look at the progress of Kura Oncology’s tipifarnib in squamous cell carcinomas of the head and neck (SCCHN) and assess the potential opportunity for approval in this setting.
To learn more from our oncology coverage and get a heads up on insights from our latest thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.
Amsterdam – this weekend it’s time to showcase some important updates in hematology from the European Hematology Association (EHA).
It’s really hard not to like continental Europe when you see scenes like this from a major conference:
T cell lymphomas is not a topic we cover very often but it looks like it will receive attention here three times in a month with news from Corvus at ASCO and now an update on the intriguing story on CXCL12-positive AML and PTCL from Kura Oncology.
We’ve been following the latter story for a while now and after the previous looks at the rationale behind the translational data, it’s now time to explore what happens in clinical practice from their ongoing phase 2 clinical trial…
To learn more and get a heads up on our latest oncology insights and conference analysis, subscribers can log-in or you can click to gain access to BSB Premium Content.